Who owns Protalix BioTherapeutics, Inc., from the filings themselves: stakes over 5% (Schedule 13D/G), the institutional managers reporting the stock each quarter (13F), and the funds holding it (N-PORT).
Investors crossing 5% ownership must disclose it. Schedule 13G filers certify the stake is passive; Schedule 13D is the general form for everyone else — founders, strategic holders, and activists alike. Each entry is the holder's most recent disclosure. Coverage begins with SEC's structured filings from December 18, 2024; a holder appears once they file or amend after that date.
MAK Capital Fund LP: 4.5% · 3,616,289 shares — MAK CAPITAL ONE LLC: 4.5% · 3,616,289 shares — Kaufman Michael A: 4.5% · 3,616,289 shares
Every institutional manager whose latest 13F reports this stock, largest position first. "% of their portfolio" is the weight inside that manager's own book — how much conviction the position represents; "% of company" is how much of Protalix BioTherapeutics, Inc. they hold. Together these 126 managers report 25.10% of shares outstanding.
| Investor | Position value | Shares | % of their portfolio | % of company | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. | $9.43M | 4,046,650 | 0.00% | 5.02% | June 30, 2026 |
| MAK CAPITAL ONE LLC | $7.69M | 3,544,139 | 1.13% | 4.40% | March 31, 2026 |
124 more institutional holders behind a free account
See every manager reporting Protalix BioTherapeutics, Inc., how much of the company they hold, and how big the position is inside their own portfolio.
Sign up freeFunds disclosing this stock in their monthly N-PORT portfolio, with the position's share of the fund's net assets. Together these 82 funds hold 6.68% of shares outstanding — counted inside the manager totals above, not on top of them, since a fund's shares also appear in its manager's 13F.
| Fund | Position value | % of net assets | % of company | As of |
|---|---|---|---|---|
| iShares Russell 2000 ETF | $3.64M | 0.01% | 2.08% | March 31, 2026 |
| Fidelity Small Cap Index Fund | $1.55M | 0.00% | 0.89% | April 30, 2026 |
80 more funds behind a free account
See every fund holding Protalix BioTherapeutics, Inc. and what share of its net assets the position represents.
Sign up freeLoading...
